These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 37670711)

  • 1. Deciphering the Role of Peroxisome Proliferator-activated Receptor α and Phosphodiesterase Type 5 Targets in Alzheimer's Disease.
    Sose PM; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2024; 23(8):956-970. PubMed ID: 37670711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.
    Żulińska S; Strosznajder AK; Strosznajder JB
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
    Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
    Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
    Liu L; Xu H; Ding S; Wang D; Song G; Huang X
    Brain Res Bull; 2019 Nov; 153():223-231. PubMed ID: 31493542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α.
    Sáez-Orellana F; Octave JN; Pierrot N
    Cells; 2020 May; 9(5):. PubMed ID: 32422896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
    Sabayan B; Zamiri N; Farshchizarabi S; Sabayan B
    Int J Neurosci; 2010 Dec; 120(12):746-51. PubMed ID: 20942592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effects of sodium hydrosulfide against β-amyloid-induced neurotoxicity.
    Li XH; Deng YY; Li F; Shi JS; Gong QH
    Int J Mol Med; 2016 Oct; 38(4):1152-60. PubMed ID: 27511125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Drug Therapy for the Management of Alzheimer's Disease.
    Kabir MT; Uddin MS; Mamun AA; Jeandet P; Aleya L; Mansouri RA; Ashraf GM; Mathew B; Bin-Jumah MN; Abdel-Daim MM
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
    Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
    ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.
    Wójtowicz S; Strosznajder AK; Jeżyna M; Strosznajder JB
    Neurochem Res; 2020 May; 45(5):972-988. PubMed ID: 32170673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
    Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
    Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
    Pasinetti GM
    J Alzheimers Dis; 2002 Oct; 4(5):435-45. PubMed ID: 12446975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Neuroprotective Strategies using Smart Drug Delivery Systems for Alzheimer's Disease.
    Khan J; Yadav S; Alam MA
    Infect Disord Drug Targets; 2024; 24(3):e231023222565. PubMed ID: 37873911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.
    Sodhi RK; Singh N; Jaggi AS
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Aug; 384(2):115-24. PubMed ID: 21607645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PPARalpha in Alzheimer's Disease.
    D'Orio B; Fracassi A; Ceru MP; Moreno S
    Curr Alzheimer Res; 2018 Feb; 15(4):345-354. PubMed ID: 28474570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
    Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D
    Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.